A Phase I/IIa Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy With Autologous Immature Dendritic Cells (VDC2008) in Chemo-naïve Men With Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone
- Men ≥ 18 years of age and any race.
- Signed Informed Consent document obtained prior to the initiation of screening
- Histologically documented primary adenocarcinoma of the prostate. A specimen of the
primary tumor must be submitted to the Central Pathology Laboratory for confirmation
of prostatic adenocarcinoma and determination of Gleason Sum grading.
- Prior history of:
1. Androgen Deprivation Therapy; or
2. Organ-preserving therapy (i.e., non-prostatectomy) for primary prostate cancer
(e.g., radiation therapy).
- In case of recurrence, subject must have evidence of prostate cancer by a positive
biopsy revealing adenocarcinoma within the past 6 months of screening and confirmed
by the Central Pathology Laboratory.
- TxNxM1a and/or TxNxM1b disease limited to three total metastatic sites as evidenced
by lymph node metastases and /or bone metastases at time of screening.
1. TxNxM1a : Lymph node metastases histologically proven and confirmed by Central
2. TxNxM1a: Lymph node metastases not histologically proven, given that the
following are satisfied in the temporal order listed:
1. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) for positive
lymph nodes negative at original diagnosis of prostate cancer;
2. Definitive local treatment undertaken;
3. Evidence of local treatment failure on the basis of rising serum PSA;
4. Prostatic biopsy positive for carcinoma;
5. Subsequent CT or MRI reveals lymph node(s) of 2 cm diameter or greater
3. TxNxM1b: Bone metastases demonstrated by radionuclide bone scan, CT, or MRI.
- Androgen-independent prostate cancer as defined by:
1. Three consecutive rises of at least 10% each in serum PSA, in which all serum
PSA measurements are separated by at least one week and results are obtained
within 60 days of study screening; OR
2. Three rises that involve an increase of 50% over the nadir serum PSA, in which
all serum PSA measurements are separated by at least one week and results are
obtained within 60 days of study screening;
3. A castrate level of testosterone (<50 ng/dl) obtained within 60 days of study
- Life expectancy of greater than or equal to 12 months.
- Adequate hematological function as defined by:
1. Total WBC > 4,500/mm3
2. Total lymphocyte count > 500/mm3
3. Hemoglobin > 12.0 g/dl
4. Neutrophils > 1,500/mm3
5. Platelets > 150,000/mm3
- Adequate renal function with creatinine < 2.0 mg/dl.
- Adequate liver function as defined by:
1. AST and ALT < 2 times the upper limit of normal;
2. Serum bilirubin < 2.0 mg/dl;
3. Alkaline Phosphatase < 2.0 upper limit of normal.
- Assessment of superficial veins as adequate for the performance of leukapheresis.
- No active major medical or psychological problems that could be complicated by study
- The presence of lung, liver or brain metastases, malignant pleural effusions or
- Moderate or severe symptomatic metastatic disease. Subjects who meet either of the
following criteria must be excluded:
1. A requirement for treatment with opioid analgesics for any reason within 21 days
prior to study screening;
2. Average weekly pain score of 4 or more as reported on the 11-point Pain
Intensity - Numerical Rating Scale (Appendix III) over the two weeks prior to
- Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 accessed at study
- Chemotherapy treatment at any time prior to study screening.
- Radiation therapy for metastatic disease, including intravenous radioactive strontium
- Initiation or discontinuation of bisphosphonate therapy within 28 days prior to study
screening. Subjects taking bisphosphonate medication must not have their dosing
regimen altered until objective disease progression is independently confirmed.
- Treatment with any of the following medications or interventions within 28 days of
1. Systemic corticosteroids (use of inhaled, intranasal and topical steroids is
2. External beam radiation therapy or surgery;
3. PC-SPES (or PC-SPEC) or Saw Palmetto extract;
4. Megestrol acetate (Megace®), diethyl stilbesterol (DES), or cyproterone acetate;
6. High dose calcitriol (i.e., > 7.0 μg/week);
7. Any other systemic therapy for prostate cancer.
- Treatment with any investigational vaccine within 2 years of enrollment to this
- Treatment with any other investigational product within 28 days of study screening.
- Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical
erosion on radiography > 50%) or spinal cord compression.
- Impending untreated spinal cord compression or urinary outlet obstruction.
- Paget's Disease of bone.
- History of stage III or greater cancer, excluding prostate cancer:
1. Basal or squamous cell skin cancers must have been adequately treated and the
subject must be disease-free at the time of study screening visit;
2. Subjects with a history of stage I or II cancer must have been adequately
treated and be disease-free for ≥ 3 years at the time of study screening
- Requirement for systemic immunosuppressive therapy for any reason
- Prior or currently active autoimmune disease requiring management with systemic
immunosuppression. Such conditions include inflammatory bowel disease, systemic
vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia,
immune-related thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus,
Sjögren's syndrome, sarcoidosis, or other rheumatological disease.
- Any infection requiring parenteral antibiotic therapy or causing fever (body
temperature > 100.5°F or 38.1°C) within 1 week prior to study screening.
- Known allergy, intolerance, or medical contraindication to receiving the contrast dye
required for the protocol-specified CT imaging
- History of asthma, anaphylaxis, or other known serious adverse reactions to vaccines.
- Any medical intervention or other condition which, in the opinion of the
Physician-Investigator could compromise adherence with study requirements or
otherwise compromise study subject safety and the study's objectives.